<SEC-DOCUMENT>0001161697-19-000436.txt : 20191015
<SEC-HEADER>0001161697-19-000436.hdr.sgml : 20191015
<ACCEPTANCE-DATETIME>20191015084302
ACCESSION NUMBER:		0001161697-19-000436
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191014
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191015
DATE AS OF CHANGE:		20191015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12305
		FILM NUMBER:		191149350

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT FOR 10-14-2019
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>October 14, 2019</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">common stock, $0.01 par value </P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">REPR</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">OTCQX</P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Repro Med Systems, Inc. d/b/a RMS Medical Products (the &ldquo;Company&rdquo;) is filing this Current Report
on Form 8-K to report that its common stock has been approved for listing and is expected to begin trading on the NASDAQ Capital
Market on October 17, 2019 under the existing symbol &ldquo;REPR.&rdquo;</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On October 14, 2019, the Company issued a press release announcing the events set forth in this Current Report
on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD><A HREF="ex_99-1.htm">Press release dated October 14, 2019</A></TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>October 14, 2019</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Karen Fisher</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Karen Fisher<BR>
Chief Financial Officer and Secretary</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 3 -</P>
<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex_99-1.htm
<DESCRIPTION>PRESS RELEASE DATED OCTOBER 14, 2019
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0px" align=center><B>Exhibit 99.1</B></P>

<P style="margin:0px">&nbsp;</P>

<P style="margin:0px"><img src="rms_logo.jpg"></P>

<P style="margin:0px">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>FOR IMMEDIATE RELEASE</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RMS MEDICAL PRODUCTS TO COMMENCE TRADING ON NASDAQ</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CHESTER, NY &ndash; October 14, 2019 -
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (&ldquo;RMS Medical&rdquo; or &ldquo;the Company&rdquo;)</B>
today announced that its common stock has been approved for listing and is expected to begin trading on the NASDAQ Capital
Market on October 17, 2019 under the current symbol &ldquo;REPR&rdquo;. The Company&rsquo;s common stock will continue to
trade on the OTCQX until market close on October 16, 2019.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;This NASDAQ listing is a significant milestone
and a reflection of our growth and evolution as a publicly traded company,&rdquo; said Don Pettigrew, President and CEO. &ldquo;We believe
that this listing will help to elevate the Company&rsquo;s profile, expand our shareholder base, enhance trading efficiency, and support
the pursuit of our long-term goals and objectives.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Our Freedom infusion system is widely accepted
as the preferred means of subcutaneous delivery of immunoglobulin therapies, and we are committed to broadening our product portfolio with solutions that
optimize therapeutic efficacy, promote compliance, and improve the overall patient experience. We reported record net sales
for the first two quarters of 2019 and believe that our strengthened management team and board of directors, proactive operating
strategy, and multiple industry tailwinds leave us well-positioned to continue to grow and maximize shareholder value.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>About RMS Medical Products</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RMS Medical Products develops, manufactures and
commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The
FREEDOM Syringe Infusion System currently includes the FREEDOM60<SUP>&reg;</SUP> and FreedomEdge<SUP>&reg;</SUP> Syringe Infusion Drivers,
RMS Precision Flow Rate Tubing<SUP>&trade;</SUP> and RMS HIgH-Flo Subcutaneous Safety Needle Sets<SUP>&trade;</SUP>. These devices are used
for infusions administered in the home and alternate care settings. For more information about RMS Medical, please visit https://www.rmsmedicalproducts.com.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The statements contained herein include prospects,
statements of future expectations and other forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 that are based on management&rsquo;s current views and assumptions and involve known and unknown risks and uncertainties, identified
by words such as &ldquo;expect&rdquo; and &ldquo;believe&rdquo;. Actual results, performance or events may differ materially from those
expressed or implied in such forward-looking statements. Factors that may cause actual results to differ materially from current
expectations and other risks are discussed in the Company&rsquo;s filings with the U.S. Securities and Exchange Commission, including
its Annual Report on Form 10-K, which filings are available from the SEC and the Company&rsquo;s website. The Company undertakes no
obligation to update any forward-looking statements.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Contacts:</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 179.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt"><B>The Equity Group Inc.</B></FONT></TD>
    <TD STYLE="width: 180.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Devin Sullivan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Kalle Ahl, CFA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Senior Vice President</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">212-836-9608</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">212-836-9614</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">mailto: dsullivan@equityny.com</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">kahl@equityny.com </FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>rms_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rms_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P *H# 2(  A$! Q$!_\0
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MQ/\ LJ_&Z:8.=Y8/!>_"GXP7&F619XV_X1OXA,VC9)^)'P]T6,ZO]7?M??\
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M'5?#3>'M<TG5FU.]T30I;-I+^TN;,#3_ +7<_P 9WQ=_X(S?'WX$?L"_'O\
M;S_:[\6ZCX9^*5A/\+=1\*?!U]2C\7>-[[5OBM\<OAQX$UWQ?\>/'=]<ZOO\
M07&E>,=<U!?">BWVJZTFNS6&K>*?&%I>VNL^$+C]8O\ @D%X8\6>./\ @@C_
M ,%!O!/@*QO]3\<>+V_;4\,>$-,TI9)-5U3Q+KO[,_@[2]&TW2TA(E.I:A?W
M,%E8"%UE^USPF)T<!AZW$?AWX>8+@&./R+/*F>9Q@^.,BX4S?BJ$Z]#*(SS*
MI0IYE# 8626'J9;@:.*ABH8EU:E><\-4G5Q4XQE3,,)FN;5<T6'Q>'AA*-3
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M<(Q@^*AFN.Q5%5ZV?Y=@9U93DL)4PJA5H14Y*,*LI-N;T34DM5K+WG)'@/\
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?2V2N[1C=+W8JRCOI]J2LSJO?K?HGY+17OUTU\S__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
